Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0036115
DC FieldValue
dc.titleMyocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers
dc.contributor.authorYiu K.H.
dc.contributor.authorAtsma D.E.
dc.contributor.authorDelgado V.
dc.contributor.authorNg A.C.T.
dc.contributor.authorWitkowski T.G.
dc.contributor.authorEwe S.H.
dc.contributor.authorAuger D.
dc.contributor.authorHolman E.R.
dc.contributor.authorvan Mil A.M.
dc.contributor.authorBreuning M.H.
dc.contributor.authorTse H.F.
dc.contributor.authorBax J.J.
dc.contributor.authorSchalij M.J.
dc.contributor.authorMarsan N.A.
dc.date.accessioned2019-11-11T06:39:48Z
dc.date.available2019-11-11T06:39:48Z
dc.date.issued2012
dc.identifier.citationYiu K.H., Atsma D.E., Delgado V., Ng A.C.T., Witkowski T.G., Ewe S.H., Auger D., Holman E.R., van Mil A.M., Breuning M.H., Tse H.F., Bax J.J., Schalij M.J., Marsan N.A. (2012). Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. PLoS ONE 7 (5) : e36115. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0036115
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161984
dc.description.abstractBackground: To evaluate the presence of myocardial structural alterations and subtle myocardial dysfunction during familial screening in asymptomatic mutation carriers without hypertrophic cardiomyopathy (HCM) phenotype. Methods and Findings: Sixteen HCM families with pathogenic mutation were studied and 46 patients with phenotype expression (Mut+/Phen+) and 47 patients without phenotype expression (Mut+/Phen-) were observed. Twenty-five control subjects, matched with the Mut+/Phen- group, were recruited for comparison. Echocardiography was performed to evaluate conventional parameters, myocardial structural alteration by calibrated integrated backscatter (cIBS) and global and segmental longitudinal strain by speckle tracking analysis. All 3 groups had similar left ventricular dimensions and ejection fraction. Basal anteroseptal cIBS was the highest in Mut+/Phen+ patients (-14.0±4.6 dB, p<0.01) and was higher in Mut+/Phen- patients as compared to controls (-17.0±2.3 vs. -22.6±2.9 dB, p<0.01) suggesting significant myocardial structural alterations. Global and basal anteroseptal longitudinal strains (-8.4±4.0%, p<0.01) were the most impaired in Mut+/Phen+ patients as compared to the other 2 groups. Although global longitudinal strain was similar between Mut+/Phen- group and controls, basal anteroseptal strain was lower in Mut+/Phen- patients (-14.1±3.8%, p<0.01) as compared to controls (-19.9±2.9%, p<0.01), suggesting a subclinical segmental systolic dysfunction. A combination of >-19.0 dB basal anteroseptal cIBS or >-18.0% basal anteroseptal longitudinal strain had a sensitivity of 98% and a specificity of 72% in differentiating Mut+/Phen- group from controls. Conclusion: The use of cIBS and segmental longitudinal strain can differentiate HCM Mut+/Phen- patients from controls with important clinical implications for the family screening and follow-up of these patients. © 2012 Yiu et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectangiotensin receptor antagonist
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectcalcium channel blocking agent
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectdiuretic agent
dc.subjectmyosin binding protein C
dc.subjectadult
dc.subjectarticle
dc.subjectcalibration
dc.subjectcardiovascular risk
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcoronary artery disease
dc.subjectdiabetes mellitus
dc.subjectelectrocardiogram
dc.subjectfemale
dc.subjectgene mutation
dc.subjectheart ejection fraction
dc.subjectheart infarction
dc.subjectheart left ventricle
dc.subjectheart muscle
dc.subjectheart muscle revascularization
dc.subjectheart ventricle wall motion
dc.subjectheterozygote detection
dc.subjecthuman
dc.subjecthyperlipidemia
dc.subjecthypertension
dc.subjecthypertrophic cardiomyopathy
dc.subjectkidney dysfunction
dc.subjectmale
dc.subjectphenotype
dc.subjectprotein expression
dc.subjectreproducibility
dc.subjectsensitivity and specificity
dc.subjectsmoking
dc.subjectsystolic dysfunction
dc.subjectechocardiography
dc.subjectechography
dc.subjectgenetics
dc.subjectheterozygote
dc.subjecthypertrophic cardiomyopathy
dc.subjectmiddle aged
dc.subjectmutation
dc.subjectpathology
dc.subjectpathophysiology
dc.subjectphysiology
dc.subjectprognosis
dc.subjectsystole
dc.subjectAdult
dc.subjectCardiomyopathy, Hypertrophic
dc.subjectEchocardiography
dc.subjectFemale
dc.subjectHeterozygote
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMutation
dc.subjectMyocardium
dc.subjectPhenotype
dc.subjectPrognosis
dc.subjectReproducibility of Results
dc.subjectSystole
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1371/journal.pone.0036115
dc.description.sourcetitlePLoS ONE
dc.description.volume7
dc.description.issue5
dc.description.pagee36115
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0036115.pdf1.65 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons